Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vegfr1 peptide vaccine + vegfr2 peptide vaccine (Fukushima Medical University)
- Development stage
- Unknown
- Lead developer
- Keio University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The vegfr1 peptide vaccine + vegfr2 peptide vaccine is an investigational immunotherapy combination developed by Fukushima Medical University for the treatment of advanced hepatocellular carcinoma (HCC). This combination vaccine consists of HLA-A*2402-restricted epitope peptides derived from Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). The therapeutic strategy involves inducing a cytotoxic T lymphocyte (CTL) response specifically targeting the tumor vasculature, where these receptors are highly expressed. By mounting an immune attack against the endothelial cells of the tumor's blood supply, the vaccine aims to inhibit angiogenesis and suppress tumor progression in patients with unresectable, recurrent, or metastatic HCC.
- Other names
- Antiangiogenic peptide vaccineVEGFR1/VEGFR2 peptide vaccineVEGFR1/2 peptide vaccine
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on vegfr1 peptide vaccine + vegfr2 peptide vaccine (Fukushima Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vegfr1 peptide vaccine + vegfr2 peptide vaccine (Fukushima Medical University).